Studies
A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL OZANIMOD (RPC1063) IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WITH AN INADEQUATE R…
Pediatrics
Gastroenterology
Digestive Disease
Pediatric Subjects
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.